BPC-157 Compound Reference
Published · Last updated · Publisher: ENOS Labs USA
What is BPC-157?
BPC-157 is a synthetic 15 residue peptide modeled on a fragment of a protein found in gastric juice. Its published literature is overwhelmingly preclinical, mostly rodent models of tendon, muscle, gut and wound injury. It is not an approved drug in the United States, and controlled human trial evidence is minimal.
- Synonyms
- Body Protection Compound 157; Pentadecapeptide BPC 157; PL 14736
- Classification
- Synthetic 15 amino acid peptide derived from a sequence in a gastric juice protein
What is BPC-157?
BPC-157 is a linear pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was described by a Croatian research group as a stable fragment of a larger gastric protein and has been studied mainly by that group since the 1990s.
Research context
Most papers examine models of soft tissue injury such as transected rat Achilles tendon, muscle crush and ligament injury, alongside gastrointestinal lesion models and skin wound models. Recent orthopaedic reviews have collected that animal literature and assessed how little of it has reached controlled human study.
Mechanisms being investigated
- Angiogenesis signaling, including effects reported on VEGF receptor and nitric oxide pathways in cell and animal models.
- Tendon fibroblast outgrowth and migration in cell culture.
- Interaction with the nitric oxide system in gastrointestinal models.
Research status
Approval status: Not approved for human use. Highest evidence tier in the cited literature: preclinical.
Preclinical. BPC-157 is not approved by the FDA for any use. A 2025 systematic review in orthopaedic sports medicine found the evidence base dominated by animal studies, with very limited human data, and a 2025 narrative review raised open questions about safety and reproducibility.
Established findings
- Its sequence and basic chemical identity are documented in PubChem.
- A large body of rodent studies from a small number of groups reports accelerated healing measures in tendon, muscle and gut injury models.
Preliminary or experimental findings
- Whether the animal findings replicate in independent laboratories.
- Any effect in humans. Controlled clinical evidence is essentially absent.
- Long term safety, including theoretical concerns linked to angiogenesis signaling.
Chemical reference information
| Molecular formula | C62H98N16O22 |
|---|---|
| Molecular weight | 1419.5 g/mol |
| CAS number | 137525-51-0 |
| PubChem CID | 9941957 |
Values taken from the PubChem record.
Testing considerations
- Identity by mass spectrometry against the expected mass of the 15 residue sequence.
- HPLC purity, with attention to deletion sequences in the proline rich region.
- Acetate versus trifluoroacetate salt form affects net peptide content by weight.
General methods are explained in purity versus identity testing.
What is still unknown
- Independent replication outside the originating group.
- Human pharmacology, distribution and safety.
- Which of several proposed mechanisms, if any, is primary.
Related resources
ENOS catalog listing: BPC-157 10MG, BPC-157 + TB-500 "Wolverine" 20MG
Research use limitations
This page summarizes published research and regulatory status. It is not medical advice and does not describe any use in people. Material supplied by ENOS Labs USA is for in-vitro laboratory research only and is not a drug product, even where a related drug has been approved.
To continue, see how to read a certificate of analysis, BPC-157 and TB-500 compared, why purity and identity are separate tests, the compound directory and the peptide testing glossary.
References
Each source below was opened and checked against its PubMed, ClinicalTrials.gov or PubChem record. Links open in a new tab.
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (PMID 30915550)Cell and Tissue Research, 2019 · PubMed
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth (PMID 14554208)Journal of Orthopaedic Research, 2003 · PubMed
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (PMID 34267654)Frontiers in Pharmacology, 2021 · PubMed
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (PMID 40756949)HSS Journal, 2025 · PubMed
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (PMID 40789979)Current Reviews in Musculoskeletal Medicine, 2025 · PubMed
- BPC 157 compound record (PubChem CID 9941957)PubChem · NIH National Library of Medicine
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.